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Gene expression in Kawasaki disease <p>Analysis of patterns of gene expression in peripheral blood from children with Kawasaki disease revealed dynamic and variable gene  expression programs involving neutrophil activation and apoptosis.</p>
Abstract
Background: Kawasaki disease (KD) is an acute self-limited vasculitis and the leading cause of
acquired heart disease in children in developed countries. No etiologic agent(s) has been identified,
and the processes that mediate formation of coronary artery aneurysms and abatement of fever
following treatment with intravenous immunoglobulin (IVIG) remain poorly understood.
Results: In an initial survey, we used DNA microarrays to examine patterns of gene expression in
peripheral whole blood from 20 children with KD; each was sampled during the acute, subacute,
and convalescent phases of the illness. Acute KD was characterized by increased relative
abundance of gene transcripts associated with innate immune and proinflammatory responses and
decreased abundance of transcripts associated with natural killer cells and CD8+ lymphocytes.
There was significant temporal variation in transcript levels during the acute disease phase and
stabilization thereafter. We confirmed these temporal patterns in a second cohort of 64 patients,
and identified additional inter-individual differences in transcript abundance. Notably, higher levels
of transcripts of the gene for carcinoembryonic antigen-related cell adhesion molecule 1
(CEACAM1) were associated with an increased percentage of unsegmented neutrophils, fewer days
of illness, higher levels of C-reactive protein, and subsequent non-response to IVIG; this last
association was confirmed by quantitative reverse transcription PCR in a third cohort of 33
patients, and was independent of day of illness.
Conclusion: Acute KD is characterized by dynamic and variable gene-expression programs that
highlight the importance of neutrophil activation state and apoptosis in KD pathogenesis. Our
findings also support the feasibility of extracting biomarkers associated with clinical prognosis from
gene-expression profiles of individuals with systemic inflammatory illnesses.
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Background
Over the past decade, genome-wide profiles of the host
response to disease have generated important new clues
about etiology and opportunities for clinically relevant classi-
fication of patients. Among the types of profiles and catego-
ries of disease subjected to this approach, DNA microarray-
based patterns of gene expression in cancer have been most
heavily exploited. Studies in this area have led to patient clas-
sification on the basis of molecular pathology and clinical out-
come, with benefits to patient care [1-3]. This approach has
been far less exploited in the setting of acute infectious dis-
eases and other acute inflammatory conditions in humans [4-
7].
In this study, we examined patterns of gene expression in
Kawasaki disease (KD), an acute self-limited vasculitis and
prominent emerging disease of young children [8]. There are
many compelling reasons to focus on KD. First, it is the most
common cause of acquired heart disease among children in
developed nations. Although the acute symptoms of rash,
fever, and mucosal changes resolve spontaneously within 2-3
weeks, the acute vasculitis results in permanent damage to
the coronary arteries in 20-25% of untreated patients. Sec-
ond, an infectious cause is suspected, but despite 30 years of
intensive study, the etiologic agent(s) remain(s) unknown.
Third, high-dose intravenous immunoglobulin (IVIG)
reduces the rate of coronary artery aneurysms (CAA) to 3-5%
if administered early in the course of the illness, but without
a specific test for the disease, many affected children go undi-
agnosed and untreated. In addition, IVIG infusion fails to
abrogate fever in approximately 10-15% of affected children
[9]; the ability to identify children at risk for resistance to
IVIG could alert clinicians to institute other therapies.
We postulated that gene-expression patterns would provide
insights into KD pathogenesis and might also provide clues
about the mechanisms of IVIG response. In this study, we
first examined gene-expression patterns in sequential blood
samples from children with KD to characterize the molecular
features of the transition from acute to convalescent KD. We
then examined samples from a second, larger cohort of KD
patients, collected before treatment, to focus on early pat-
terns of gene expression and to search for potential early
associations with subsequent CAA formation and IVIG resist-
ance. A molecular marker that emerged from this second
cohort in association with IVIG response was evaluated in a
third cohort of KD patients.
Results
Gene-expression patterns associated with acute 
Kawasaki disease
We collected whole blood from 20 individuals (cohort 1) at
each of three time points during the course of their illness:
immediately before treatment (acute samples), 11-24 days
post-onset of fever (5-19 days post-IVIG treatment, subacute
samples), and more than 24 days post-onset (convalescent
samples). Five patients each provided one additional sample
at various times: subacute phase (1), convalescent phase (1),
and 1 or 2 days after IVIG treatment (3). A total of 65 whole-
blood RNA samples were analyzed using DNA microarrays
(Table 1, cohort 1); to identify genes whose expression varied
during the course of KD, we selected the 1,255 genes (1,594
clones) whose transcript abundance varied at least threefold
from the median in two or more of the 65 samples, and organ-
ized both genes and samples using hierarchical clustering
(Figure 1).
Acute and convalescent samples had distinct patterns of gene
expression: 19 of the 20 acute samples in cohort 1 clustered
together (clusters A1 and A2, Figure 1), whereas 33 of the 45
subacute and convalescent samples formed the other major
cluster (B, Figure 1). Sixteen of the acute samples segregated
into a sub-cluster (A1, median illness day 6 (illness day 1 =
first day of fever), range 4-12). Three other acute samples
segregated in a different sub-cluster with five subacute and
Table 1
Characteristics of patients
Cohort 1 (n = 20)* Cohort 2 (n = 64)* Cohort 3 (n = 33)*
Sex 14 male, 6 female 44 male, 20 female 19 male, 14 female
Age in years† 3.5 (0.4-12.6) 2.1 (0.35-15.6) 1.7 (0.1-4.5)
Coronary artery status‡ 11 N, 7 D, 2 A 33 N, 22 D, 9 A 26 N, 3 D, 4 A
IVIG response§ 14 R, 4 NR 45 R, 8 NR 22 R, 11 NR
Illness day, acute sample† Day 6 (4-12) Day 6 (2-14) Day 5 (3-7)
Illness day, subacute sample† Day 20 (12-24)¶ NA NA
Illness day, convalescent sample† Day 47 (32-64)¶ NA NA
*Seven individuals were in both cohort 1 and cohort 2; three additional individuals were in both cohort 1 and cohort 3. †Data presented as median 
(range). ‡Arterial diameter determined by echocardiogram. N, normal; D, dilated; A; aneurysm. §R, IVIG responder; NR, IVIG non-responder. Two 
patients in cohort 1 and 11 in cohort 2 were treated with IVIG after illness day 10 and excluded from analysis of IVIG response. ¶Additional samples 
were obtained from three patients less than 48 h after treatment with IVIG on illness days 7, 8, and 13; one additional sample was obtained from a 
fourth patient at a 1-year follow-up. NA, not applicable.http://genomebiology.com/2007/8/12/R261 Genome Biology 2007,     Volume 8, Issue 12, Article R261       Popper et al. R261.3
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one convalescent sample (A2, median illness day 15, range 8-
24); these samples were collected from three individuals
diagnosed and sampled more than 7 days after the onset of
fever.
Two sets of genes (see Figure 1, gene clusters 1 and 2, vertical
yellow bars) with an average expression correlation coeffi-
cient of greater than 0.8 were significantly associated with the
segregation of samples into clusters A and B (clusters 1 and 2:
p = 0.005 and 0.01, respectively). Average transcript levels in
cluster 1 were high early in the illness and declined as a func-
tion of illness day, whereas cluster 2 transcripts were less
abundant early in the illness and increased as a function of ill-
ness day, although these trends did not achieve statistical sig-
nificance in this group of specimens (Figure 2a, p = 0.08 for
both clusters). Both sets of genes were stable over time in the
convalescent phase. The 245 genes (354 clones) in cluster 1
included many whose expression has been associated with
neutrophils and inflammatory processes, including adrenom-
edullin (ADM), B-cell lymphoma 6 (BCL6), colony stimulat-
ing factor 2 receptor, beta (CSF2RB), formyl peptide receptor
1 (FPR1), grancalcin (GCN), granulin (GRN), interferon-
induced transmembrane protein 2 (IFITM2), IL1 receptor 2
(IL1R2) and IL1 receptor antagonist (IL1RN), matrix metallo-
Patterns of transcript abundance in whole-blood samples from children with KD (cohort 1) Figure 1
Patterns of transcript abundance in whole-blood samples from children with KD (cohort 1). Genes and samples were organized using hierarchical 
clustering; each row represents a single gene, and each column a single sample. Black indicates the median level of expression, red indicates greater 
expression than the median, green less expression, and gray missing data. Horizontal bars under the sample dendrogram at the top indicate samples from 
the same individual that cluster together; open circles represent samples obtained 1 or 2 days after IVIG treatment. Pretreatment acute KD samples are in 
yellow; early post-treatment subacute samples in light blue; late post-treatment convalescent samples in purple. Horizontal bars at the bottom of the figure 
indicate the sample groups mentioned in the text. A1 and A2 are clusters of acute samples; B is a cluster of subacute and convalescent samples. Vertical 
yellow bars (1 and 2) on the right mark the two gene clusters most strongly associated with the grouping of the pretreatment samples. The intrinsic score 
was graphed as a moving average of nine genes along the y-axis. The black vertical bars on the right lettered a, b, and c mark the three gene clusters with 
intrinsic scores more than 2 standard deviations away from the mean score of 0.742.
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proteinase-9 (MMP9), pre-B cell colony-enhancing factor 1
(PBEF1), and the S100 calcium binding protein A11
(S100A11). The 10 genes in cluster 2 included those for the T-
cell receptor gamma subunit (TRG), killer cell lectin-like
receptor subfamily G, member 1(KLRG1), the IL2 receptor
beta subunit (IL2RB), and V-myb myeloblastosis viral onco-
gene homolog (avian)-like 1 (MYBL1) - all genes preferen-
tially expressed in CD8 T cells and NK cells [10,11] (see
Additional data file 1 for a complete list of the genes in clus-
ters 1 and 2).
Individuality of gene expression in KD patients
There was no evidence of sample clustering by day of illness
among the convalescent samples. However, we observed pair-
ing of subacute and convalescent samples from six of the 20
individuals. This pattern suggested the presence of intrinsic
differences in gene expression of individuals that might
reflect underlying DNA polymorphisms [7]. We calculated an
'intrinsic' score for each gene, based on the ratio of within-
individual to between-individual variation among the suba-
cute and convalescent samples. Three gene clusters had an
average intrinsic score or more than two standard deviations
from the mean score of all genes in the original dataset that
met our quality criteria (see Figure 1, gene clusters a-c; see
Additional data file 2 for a complete list of the genes). Two of
these intrinsic gene sets were composed of HLA loci (both
class I HLA-B and class II HLA-DR and DQ) and Y-linked
genes that were expressed at higher levels in the male patients
(see Figure 1, gene clusters b and c, respectively). The third
cluster (see Figure 1, gene cluster a) was composed of 65
genes (78 clones), including those that encode proteins
involved in antigen processing (HLA-DOA and the immu-
noglobulin heavy-chain mu locus) and regulation of the
immune response (cytotoxic T-lymphocyte associated protein
4, the Ets transcription factor Spi-B, and IL24).
When we re-clustered the 65 samples using these three gene
sets, specimens from all three time periods (acute, subacute,
and convalescent) from each of six subjects clustered
together. For 14 of 20 subjects, the acute sample was most
similar to a subacute or convalescent sample from the same
individual, indicating that expression of the most person-
intrinsic genes, including those involved in antigen presenta-
tion, did not differ in the acute and convalescent phases of the
disease (Figure 3).
Variation in gene expression in acute KD and 
correlations with clinical parameters
Cohort 1 provided an overview of gene-expression patterns in
KD, from the acute phase through to convalescence. The
observed patterns emphasized the differences between early
and late phases of the disease and suggested that gene expres-
Patterns of transcript abundance as a function of illness day (days post-onset of fever) Figure 2
Patterns of transcript abundance as a function of illness day (days post-onset of fever). (a) Average transcript abundance of the two gene clusters 
associated with segregation of the acute and convalescent samples in cohort 1 (yellow bars in Figure 1). Closed symbols indicate pretreatment samples; 
open symbols indicate post-treatment samples. Black squares and red triangles represent transcripts expressed at higher (cluster 1) and lower (cluster 2) 
levels in acute KD, respectively. Solid (acute) and dashed (subacute and convalescent) black lines and red lines show the trend in expression levels of the 
genes in cluster 1 and cluster 2, respectively. (b,c) Average transcript abundance of (b) gene cluster 1 and (c) gene cluster 2 in cohort 2. The significance 
of the trend of expression over time in cohort 2 (p = 0.01 in (b), and p = 0.03 in (c)) was determined using Spearman rank correlations.
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sion in the early phase is highly dynamic. To characterize
early events that shape the pathogenic process, we examined
gene-expression patterns in a larger set of blood samples, col-
lected before treatment (acute phase) from 64 patients (Table
1, cohort 2). This second set included seven acute-phase sam-
ples from cohort 1 that were reprocessed in parallel with
acute-phase samples from 57 new patients; comparison of the
original and re-derived expression profiles from the seven
patients demonstrated reproducibility of these microarray
data (Additional data file 3).
The relative transcript levels of the 1,241 most variably
expressed genes (more than threefold variation from the
median, in three or more of the 64 samples: 1,652 clones) are
displayed in Figure 4. In contrast to the acute samples in
cohort 1, the acute samples in cohort 2 did not segregate by
day of illness. Instead, the two main sample clusters (Figure
4, clusters C and D) were most strongly associated with differ-
ences in lymphocyte percentage and the age of the patient at
onset of illness. Patients in cluster C had a lower percentage
of lymphocytes and tended to be older than those in cluster D
(p = 0.05 and 0.06, respectively, rank-sum test).
To identify gene-expression patterns associated with the dis-
tinctions between clusters C and D and to elucidate the
molecular processes underlying clinical parameters used to
assess and predict the course of KD, we calculated the corre-
lation coefficient of the expression levels of each gene with
each available demographic and clinical laboratory
Clustering of KD samples on the basis of intrinsic gene-expression patterns Figure 3
Clustering of KD samples on the basis of intrinsic gene-expression patterns. The 65 samples from 20 patients in Figure 1 were reorganized using the three 
gene clusters identified as having the lowest (strongest) intrinsic scores. a, b, and c indicate the same gene clusters as in Figure 1. Colors are as in Figure 1. 
Horizontal black bars indicate samples from the same patient that clustered together.
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parameter. Eight parameters showed particularly strong
associations (p  < 0.01) with subsets of genes analyzed in
cohort 2 (see Figure 4).
Two large sets of genes were associated with differences in the
relative abundance of the two major blood cell
subpopulations, neutrophils (234 genes, 321 clones; cluster 1
in Figure 4) and lymphocytes (319 genes, 387 clones; cluster
5 in Figure 4). The neutrophil-associated gene set was also
positively correlated with age at onset of illness, and con-
tained genes involved in the innate immune response, includ-
ing those for CD14, Toll-like receptors 1, 2, 4, 6 and 8, and Fc-
receptor II subunits A and B. Other genes in the cluster
included those for proteins involved in cell adhesion
(PECAM1, CEACAM4, CD36 and metalloproteases ADAM8,
ADAM19, and MMP9), leukocyte chemotaxis (FPR1, HCK,
PF4, SELP, SELL, VNN2 and VNN3), and genes encoding
proinflammatory cytokines (IL1A and B, S100A12, and
ADM). Names and symbols of both sets of genes, as well as
those discussed below, are listed in Additional data file 4.
Age-associated patterns of expression
The gene clusters whose expression varied with the relative
abundance of neutrophils and lymphocytes were also associ-
ated with the age of the patient (r = 0.59 and -0.56, respec-
tively). Two other sets of genes (clusters 3 and 4) were
strongly associated with age but not with any of the other
measured parameters. The 24 genes (42 clones) in cluster 3
(see Figure 4) were more highly expressed in older children,
and included membrane metalloendopeptidase (MME/
CD10) and protease inhibitor 3 (PI3/SKALP), as well as a
number of antimicrobial peptides (see Additional data file 4).
Cluster 4 (see Figure 4) consisted of 11 genes more highly
expressed in younger children, and included the immu-
noglobulin lambda locus (IGL), the gene for the pre B-cell
receptor light chain subunit (IGLL1), as well as the gene for
Association of transcript abundance and clinical parameters in patients with acute KD (cohort 2) Figure 4
Association of transcript abundance and clinical parameters in patients with acute KD (cohort 2). (a) Genes and samples are organized using hierarchical 
clustering as in Figure 1. Sample clusters C and D are explained in the text. Numbered vertical bars at the right of the heat map indicate gene sets 
described in the text and in Additional data file 4. b) Correlation coefficients were calculated for the expression of each gene and each of the following 
clinical parameters: percentage segmented neutrophils, percentage unsegmented neutrophils (band), percentage total neutrophils, percentage 
lymphocytes, age at onset, illness day, erythrocyte sedimentation rate (ESR), and level of C-reative protein (CRP). A p value was calculated using 
permutation, and assigned a negative or positive value corresponding to the direction of the correlation. Results are portrayed as a moving average along 
the y-axis, with a window size of 15 clones, and were plotted for a given parameter if the p value was less than 0.01 (marked by dotted line) over 10 or 
more consecutive array elements.
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pro-apoptotic caspase adaptor protein (PACAP), an anti-
inflammatory protein that negatively regulates IL6.
Patterns related to day of illness
Many of the genes that distinguished acute and convalescent
KD in cohort 1 appeared to have time-dependent patterns of
expression within the acute phase of the disease (see Figure
2a). With the larger set of samples in cohort 2, we confirmed
these associations using DNA microarray-based data (see
Figure 2b,c). Genes highly expressed in acute KD in cohort 1
also comprised most (54 of 60) of those found in the day-
related cluster identified in cohort 2 (cluster 2, Figure 4).
These 60 day-correlated genes were also associated with a
higher proportion of unsegmented neutrophils (bands) in the
blood; regression analysis indicated that average transcript
abundance for this set of genes was independently associated
with both illness day and band percentage (p < 0.001 for each
parameter). Among the 60 genes were a number that have
been implicated in regulation of apoptosis (BCL2A1, BIRC1,
IKBKG, SFRP1, and SH3GLB1), as well as others associated
with proinflammatory processes (ANXA3, HP, IL13, IL18R1,
CEACAM1). Kobayashi et al. [12] recently demonstrated that
transcriptional programs leading to inhibition of apoptosis
and an increase in expression of proinflammatory genes are
features of neutrophils exposed to granulocyte-macrophage
colony stimulating factor (GM-CSF). Of the 60 genes, 23 were
among those upregulated in response to GM-CSF, compared
with 123 of the 1,241 genes in the larger set of most variable
genes (p < 10-8, hypergeometric).
Genes associated with response to IVIG and coronary 
artery outcome
Echocardiograms of the 64 patients in cohort 2 revealed nor-
mal coronary arteries in 33, dilatation in 22 and CAA in nine.
Eight of the 53 patients treated on or before illness day 10 did
not defervesce within 48 hours following treatment with
IVIG, and were classified as non-responders (Table 1).
We looked for potential prognostic biomarkers associated
with response to IVIG and with coronary artery outcome
using significance analysis of microarrays (SAM) [13]. We did
not identify any genes whose expression differed significantly
using the criterion of coronary artery outcome. However, we
identified five genes whose level of expression was associated
with a non-response to IVIG (median false-discovery rate
20%): these were the genes for FK506 binding protein 5
(FKBP5), beta-actin (ACTB), carcinoembryonic antigen-
related cell adhesion molecule 1 (biliary glycoprotein,
CEACAM1/CD66), vesicle-associated membrane protein 5
(VAMP5), and polo-like kinase 2 (PLK2, or serum-inducible
kinase SNK). We performed quantitative reverse transcrip-
tion PCR (RT-PCR) for all five genes using 11 RNA samples
that had also been analyzed with microarrays (six responders
and five non-responders). CEACAM1 and FKBP5 showed a
significant association with treatment response on the basis
of RT-PCR data, but only CEACAM1 showed a strong correla-
tion with the array results (data not shown).
To confirm this finding for CEACAM1  in an independent
group of patients, we measured CEACAM1 mRNA levels in
pre-treatment samples from 11 additional IVIG non-respond-
ers and 22 responders, matched for illness day and age
(cohort 3, Table 1). CEACAM1 was again expressed at signifi-
cantly higher levels in the non-responders (Figure 5). The
CEACAM1  transcript is alternatively spliced; CEACAM1
mRNA exists either in a long (L) form with a cytoplasmic tail
that contains immunoreceptor tyrosine-based inhibitory
motifs (ITIMs), or a short (S) form in which the tail is
truncated (reviewed in [14]). The two forms have different
signaling properties, and occur at different ratios in different
cell types. To determine if both isoforms were associated with
IVIG non-response, we measured levels of each of these tran-
scripts separately, using specific quantitative RT-PCR assays;
both transcripts were found at higher levels in the patients
who subsequently failed to respond to IVIG treatment (see
Figure 5).
Discussion
Our unsupervised analysis of expression profiles from
sequential samples of KD patients (cohort 1) revealed segre-
gation of acute and convalescent samples, driven by higher
levels of gene transcripts associated with neutrophils and
innate immune responses during the acute phase of the ill-
ness. The subacute and convalescent phases of KD were char-
acterized by increased abundance of transcripts associated
with CD8 T cells and NK cells. These patterns of expression in
part reflect previously observed fluctuations in leukocyte sub-
populations during the course of KD; expansion of the neu-
trophil population is a characteristic feature of acute KD, and
previous studies have reported an elevated CD4:CD8 ratio in
the peripheral blood during the acute phase, and an increase
in both CD8 T cells and CD16 NK cells in the convalescent
phase [15-17]. Our findings are consistent with the hypothesis
that CD8 T cells and NK cells are sequestered in the arterial
walls or bound to endothelial cells during acute KD, and
return to the circulation later in convalescence [15,16]. All
patients were treated with IVIG after the acute samples were
obtained; it is therefore possible that the subsequent shifts in
transcript abundance were due to the direct effects of IVIG on
cellular processes. However, three of four pre-treatment
acute samples obtained after illness day 7 clustered with
subacute samples, and the two post-treatment samples
obtained before illness day 10 clustered with acute samples.
This suggests that the changes in the levels of most transcripts
associated with acute KD were more closely associated with
the natural history of the disease than with the effects of IVIG.
These acute disease-associated gene-expression patterns
were superimposed on underlying person-specific features
that did not vary significantly throughout the course of KD.Genome Biology 2007, 8:R261
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Transcript abundance for genes identified as 'intrinsic' to an
individual were not associated with treatment response or
development of aneurysms, but may be linked to specific
genetic polymorphisms, which are believed to play an impor-
tant role in determining susceptibility to KD [8,18].
Two previous studies examined genome-wide gene-expres-
sion patterns in acute and convalescent samples from four
patients [19,20]. Both reported increased transcript abun-
dance in acute KD for a number of the genes we identified in
our study, including ADM  and  S100A12.  ADM  encodes a
vasodilatory peptide, and S100A12 contributes to proinflam-
matory cascades; both gene products are known to be ele-
vated in the serum of KD patients [19,21]. While previous
studies focused on the increased expression of these genes in
monocytes, they are also expressed at high levels in granulo-
cytes [11]. Given the abundance of neutrophils in acute KD,
and the correlation of these genes with neutrophil count in
our study, it is likely that much of the expression of ADM and
S100A12 in acute KD can be attributed to neutrophils.
By sampling whole blood, we were able to identify the sub-
stantial contribution of neutrophils to the overall transcrip-
tional program associated with KD; the sampling of whole
blood also offers important practical advantages in the clini-
cal workplace. Yet the use of mixed cell populations also lim-
ited our ability to evaluate the relative importance and
activation state of specific cell types [4]. The differences in
neutrophil and lymphocyte abundance in the sequential
blood samples from KD patients (cohort 1) accounted for
Levels of CEACAM1 mRNA in pretreatment whole-blood samples from KD patients who subsequently responded (R) or failed to respond (NR) to IVIG  treatment Figure 5
Levels of CEACAM1 mRNA in pretreatment whole-blood samples from KD patients who subsequently responded (R) or failed to respond (NR) to IVIG 
treatment. Transcript levels were measured by quantitative RT-PCR, and normalized to TAF1B transcript levels. Black triangles, assay for both long (L) and 
short (S) splice forms of CEACAM1; gray triangles, L-form; open triangles: S-form. Horizontal bars indicate median relative expression level.
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approximately half of the variation in average expression of
the genes in clusters 1 and 2 (r2 = 0.53 and 0.50, respectively),
suggesting that differences in activation, or other sources of
heterogeneity, also play a role in the observed variation in
transcript abundance. Further studies of transcript patterns
in purified neutrophils and lymphocyte populations from KD
patients will help clarify the role of activation states for spe-
cific cell types in the different phases of the illness.
Because our study included many more patients and samples
than in previous studies, we were able to examine patterns of
gene expression at much higher resolution and able to discern
inter-patient variation within the acute phase of the disease.
The sets of neutrophil- and CD8 T cell- or NK-associated
genes varied with day of illness, emphasizing the dynamic and
variable nature of the acute phase of the disease. Gene expres-
sion during the acute phase of KD also correlated with fluctu-
ations in the major leukocyte populations, age, and
concentrations of C-reactive protein (CRP). All these param-
eters have been associated with the risk of coronary artery
damage [22-24]. The sets of correlated genes provide molec-
ular signatures for these clinical features, and may also pro-
vide insight into physiological properties of the immune
system. For example, the increased abundance of immu-
noglobulin λ chain transcripts in younger children with KD
mirrors the inverse correlation we previously reported
between λ expression and age among healthy adults [7], sug-
gesting that this may be a more general phenomenon. Con-
versely, a set of genes primarily expressed in neutrophils was
positively correlated with age. These genes include several
that encode antimicrobial peptides, MME, and PI3, and may
reflect differences in neutrophil function as children age. Lev-
els of a number of neutrophil surface proteins, including
MME, are known to change with age, and changes in neu-
trophil function have been identified in elderly individuals,
but have not been examined in younger age groups [25,26].
This study was limited to patients with KD; studies that
include age-matched healthy and febrile controls would clar-
ify whether the observed associations of gene expression and
clinical parameters are unique to KD.
The genes that vary in expression during acute KD also pro-
vide leads for identifying biomarkers associated with clinical
outcome and with biological processes underlying KD
pathology. Of particular note, increased abundance of
CEACAM1 transcripts was associated with subsequent non-
response to IVIG in two independent sets of patients. The
clinical utility of CEACAM1 transcript levels for predicting
IVIG non-response remains to be determined; there was a
200-fold range in the level of CEACAM1 transcript, but our
sample size was too small to obtain a precise estimate of the
risk associated with a 10-fold increase in transcript abun-
dance (odds ratio = 5.9, 95% CI = 1.2-30.5). The results of
previous studies that have attempted to build a decision
instrument for predicting IVIG response suggest that no sin-
gle marker is likely to suffice [27]; the overlap in CEACAM1
expression for IVIG responders and non-responders suggests
it may be most useful when combined with other markers (see
Figure 4).
CEACAM1 was among the genes whose expression was corre-
lated with day of illness and the relative abundance of unseg-
mented neutrophils, and CEACAM1 expression levels were
also correlated with levels of CRP. Fewer days of illness at
diagnosis, an increase in unsegmented neutrophils, and
h i g h e r  l e v e l s  o f  C R P  h a v e  a l l  b e e n  a s s o c i a t e d  w i t h  n o n -
response to IVIG in multiple studies [27-30]; thus, CEACAM1
may provide clues about a common biological process under-
lying treatment response. The CEACAM1 protein is a surface
molecule expressed on a wide variety of cells, but at particu-
larly high levels on neutrophils, and increases in CEACAM1
expression have been associated with delayed apoptosis in
both human and rat neutrophils [12,31]. Neutrophil apoptosis
is an important feature in the resolution of inflammatory
processes; the association of CEACAM1 transcript abundance
with IVIG response in this study supports the idea that neu-
trophil apoptosis may be an important factor in the
mechanism of action of IVIG in KD patients. Two studies
reported that immunoglobulin induces apoptosis in vitro in
neutrophils obtained from pre-treatment KD patients, but
not from healthy controls [32,33]. One of these studies also
found a significant association between the fraction of neu-
trophils undergoing apoptosis and defervescence following
IVIG treatment. Further studies will be required to determine
whether neutrophils in KD patients expressing CEACAM1 are
less susceptible to apoptosis following treatment with IVIG
and whether CEACAM1 mediates this process.
Conclusion
KD has been a leading cause of acquired heart disease in chil-
dren for more than 30 years, but the pathogenic mechanisms
remain obscure. Our goal was to build a comprehensive por-
trait of the host response in KD by examining genome-wide
transcript abundance patterns in whole blood. The results
emphasize two features: first, the dynamic and variable
nature of the acute phase of the disease, and second, the role
of neutrophils and their activation programs. Variation in
transcript abundance was associated not only with day of ill-
ness, but also with clinical parameters that have been used in
the management of KD and in efforts to predict the course of
disease. The sets of correlated genes provide molecular signa-
tures for these clinical features and help to identify biological
processes with a role in KD pathogenesis. Higher CEACAM1
transcript levels were also associated with subsequent non-
response to IVIG treatment, suggesting the feasibility of
identifying prognostic markers for an infectious or acute
inflammatory process on the basis of host gene-expression
profiles.Genome Biology 2007, 8:R261
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Materials and methods
Study population and sample collection
KD patients (n = 107) were enrolled at two clinical sites (Rady
Children's Hospital, San Diego, CA and Children's Hospital
Boston, MA) after parental informed consent. All patients
had fever and four or more of the five principal clinical crite-
ria for KD (rash, conjunctival injection, cervical lymphaden-
opathy, changes in the oral mucosa, and changes in the
extremities) or three criteria plus coronary artery abnormali-
ties documented by echocardiography [34]. The human sub-
jects protocol was reviewed and approved by the Institutional
Review Boards at UCSD, Children's Hospital Boston, and
Stanford University. Clinical data including gender, ethnicity,
race, age, day of illness (first day of fever = illness day 1),
results of laboratory testing, response to IVIG therapy, and
coronary artery status were recorded for all subjects. IVIG
non-response was defined as persistent or recrudescent fever
(T ε 100.4°C F rectally or orally) 48 h following completion of
the IVIG infusion (2 g/kg). The mean duration of fever in
untreated KD patients is 11 days; patients treated more than
10 days after the onset of fever have therefore been excluded
from trials of IVIG efficacy, and were excluded from the anal-
ysis of IVIG response in this study [34]. The internal diame-
ters of the right coronary and left anterior descending arteries
were classified by echocardiography as normal (< 2.5 stand-
ard deviations (z score) from the mean, normalized for body
surface area [35]), dilated (2.5 δ z score < 4.0), or aneurysmal
(saccular or fusiform dilatation of a coronary artery segment
with z score ε 4.0).
Blood was obtained for determination of complete blood
count and differential, CRP, erythrocyte sedimentation rate
(ESR), and gamma glutamyltranspeptidase (GGT), and for
RNA studies (Paxgene Blood RNA System, PreanalytiX
GmbH, 8634 Hombrechtikon, CH). PAXgene tubes were
stored at 4°C C for no more than 5 days and RNA was purified
according to the manufacturer's instructions.
DNA microarray hybridization
RNA transcripts in the samples and a standard reference RNA
(Universal Human Reference RNA, Stratagene, La Jolla, CA)
were amplified using the MessageAmp aRNA amplification
kit (Ambion, Austin, TX). Sample and reference transcripts
were then reverse-transcribed, labeled with fluorescent dyes
(Cy5 and Cy3, respectively), mixed together, and hybridized
to cDNA microarrays as previously described [36,37]. The
arrays used for these studies contain 37,632 spots derived
from cDNA clones representing approximately 18,000
unique human genes [2]. Images of hybridized arrays were
obtained using a Genepix 4000B microarray scanner, and
analyzed with Genepix 5.0 (Axon Instruments, Union City,
CA). The data were submitted to the Stanford Microarray
Database [38].
Microarray data filtering and analysis
Data were filtered to include only clones that met the follow-
ing criteria for at least 80% of the samples tested: signal
intensity 2.5-fold above background in either the Cy5 (sam-
ple) or Cy3 (reference) channel, and a regression correlation
for the two channels of at least 0.6 across each measured ele-
ment. A normalization factor was applied so that the mean
log2 ratio for each array (sample) was zero, and data for each
clone were then median-centered across all observations.
Selected data were organized using a hierarchical clustering
algorithm based on a Pearson correlation metric, with aver-
age linkage clustering [39], and visualized using Java
Treeview [40].
The EASE software program was used to identify Gene Ontol-
ogy (GO) categories enriched in specified subsets of the data
[41]. An EASE score was calculated for each GO term repre-
sented in the dataset; EASE scores represent an adjustment
to the Fisher exact probability that penalizes terms containing
only a few genes. A global false-discovery rate was calculated
to adjust for multiple testing, and to generate the reported p
values. Enrichment within gene clusters for genes found in
other gene expression datasets was determined using the
hypergeometric distribution.
Intrinsic scores were calculated as previously described [7].
For each gene, the ratio of the mean squared pairwise differ-
ence in transcript levels among multiple samples from a sin-
gle individual to the mean squared pairwise difference among
individuals. The mean intrinsic score in cohort 1, for the
20,361 clones (12,186 genes) well measured in at least 80% of
the subacute and convalescent samples, was 0.742, with a
standard deviation of 0.473.
The association of expression levels of a given gene and a
given clinical parameter was defined by the Pearson correla-
tion coefficient. Parameter values were then randomly per-
muted 1,000 times among the patients, while the expression
data were held constant. The fraction of times the permuted
data yielded a correlation coefficient greater than that
obtained with the true data was used to calculate a p value.
The negative logarithm (base 10) of the p value, with the sign
of the original coefficient to indicate direction, represented
this association graphically.
The association of laboratory parameters with the occurrence
of either a coronary artery lesion or failure to respond to IVIG
therapy was assessed using a Student's t-test; CRP levels were
log-transformed to approximate a normal distribution more
closely. SAM was used to identify genes significantly associ-
ated with treatment response [13]. Linear regression models
and Spearman rank correlations were tested using STATA v.7
(STATA, College Station, TX).http://genomebiology.com/2007/8/12/R261 Genome Biology 2007,     Volume 8, Issue 12, Article R261       Popper et al. R261.11
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Quantitative RT-PCR
Levels of CEACAM1,  FKBP5,  ACTB,  VAMP5, and PLK2
mRNA were measured using TaqMan 5'-nuclease Gene
Expression Assays (Applied Biosystems, Foster City, CA).
Three different primer sets were used to measure CEACAM1
transcript levels for the alternatively spliced long (L) form,
the short (S) forms missing the cytoplasmic tail, and a subset
of both long and short forms, respectively. Relative abun-
dance of the target transcripts was calculated by comparison
to a standard curve, and normalized to the expression level of
TATA box binding protein-associated factor, RNA polymer-
ase I, B (TAF1B). Full details and Applied Biosystems catalog
numbers for all assays are available in Additional data file 5.
The data are also available in NCBI's Gene Expression Omni-
bus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are
accessible through GEO Series accession number GSE9873.
Additional data files
Additional data is available with this paper online. Additional
data file 1, genes elevated in acute and convalescent KD, is a
spreadsheet containing a list of the genes in clusters 1 and 2
in Figure 1 (cohort 1). Gene symbol, gene name, and gene
cluster are listed for each gene. Additional data file 2, person-
intrinsic genes, is a spreadsheet containing the list of genes
identified as having person-specific patterns of expression
(see Figure 3).
Additional data file 3 is a figure showing the reproducibility of
whole blood genome-wide transcript abundance patterns.
Additional data file 4 is a spreadsheet listing gene sets corre-
lated with clinical parameters (see Figure 4). Additional data
file 5 contains detailed information on the quantitative RT-
PCR methods used in this study.
Additional data file 1 Genes whose expression is elevated in acute and convalescent KD A spreadsheet containing a list of the genes in clusters 1 and 2 in  Figure 1 (cohort 1). Gene symbol, gene name, and gene cluster are  listed for each gene. Click here for file Additional data file 2 Person-intrinsic genes A spreadsheet containing the list of genes identified as having per- son-specific patterns of expression (see Figure 3). Click here for file Additional data file 3 A figure showing the reproducibility of whole blood genome-wide  transcript abundance patterns Seven RNA samples from different KD patients were amplified,  labeled, and hybridized to cDNA microarrays on two separate occa- sions. The set of 601 array elements that were present in both the  final dataset for cohort 1 (Figure 1) and cohort 2 (Figure 4) were  used to center and organize each of the two sets of seven samples.  The two datasets were then jointly organized using hierarchical  clustering. Each original RNA sample is indicated by a unique  color. In all cases, the replicates of each sample were paired, indi- cating that relative patterns of expression were maintained across  the two experiments. Click here for file Additional data file 4 A spreadsheet listing gene sets correlated with clinical parameters  (see Figure 4) A list of the genes whose expression was correlated with clinical  parameters in cohort 2. Gene symbol, gene name, and gene cluster  (see Figure 4) are listed for each gene. Click here for file Additional data file 5 Detailed information on the quantitative RT-PCR methods used in  this study. Detailed information on the quantitative RT-PCR methods used in  this study. Click here for file
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